Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:DYNNASDAQ:GPCRNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.91+9.1%$1.42$1.11▼$5.00$465.75M1.771.50 million shs2.00 million shsDYNDyne Therapeutics$12.70+6.2%$10.33$6.36▼$47.45$1.44B1.191.63 million shs2.22 million shsGPCRStructure Therapeutics$21.79+0.1%$21.73$13.22▼$62.74$1.25B-1.69938,256 shs1.05 million shsVERAVera Therapeutics$31.74+67.5%$22.06$18.53▼$51.61$2.02B1.28841,685 shs12.87 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+9.77%+24.03%+41.48%+4.37%-54.42%DYNDyne Therapeutics+7.45%+8.64%+7.08%+6.81%-60.16%GPCRStructure Therapeutics+0.32%-11.24%-19.56%-3.11%-36.29%VERAVera Therapeutics+66.88%+61.61%+25.40%+10.98%-16.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.5772 of 5 stars3.51.00.00.02.83.30.6DYNDyne Therapeutics3.0804 of 5 stars4.51.00.00.02.83.30.0GPCRStructure Therapeutics1.9577 of 5 stars3.51.00.00.02.31.70.6VERAVera Therapeutics2.14 of 5 stars3.61.00.00.03.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32387.96% UpsideDYNDyne Therapeutics 3.07Buy$45.54258.57% UpsideGPCRStructure Therapeutics 3.00Buy$79.86266.49% UpsideVERAVera Therapeutics 3.10Buy$65.00104.79% UpsideCurrent Analyst Ratings BreakdownLatest AUTL, VERA, DYN, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.006/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.006/2/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.005/2/2025GPCRStructure TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M56.41N/AN/A$0.64 per share2.98DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%8/14/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)GPCRStructure Therapeutics-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/7/2025 (Estimated)VERAVera Therapeutics-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%8/14/2025 (Estimated)Latest AUTL, VERA, DYN, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69DYNDyne TherapeuticsN/A17.0217.02GPCRStructure TherapeuticsN/A27.6327.63VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%DYNDyne Therapeutics96.68%GPCRStructure Therapeutics91.78%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%DYNDyne Therapeutics14.14%GPCRStructure Therapeutics9.43%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableVERAVera Therapeutics4063.77 million49.58 millionOptionableAUTL, VERA, DYN, and GPCR HeadlinesRecent News About These CompaniesWhy Vera Therapeutics, Inc. (VERA) Skyrocketed On MondayJune 3 at 3:58 AM | insidermonkey.comWhy Vera Therapeutics, Inc. (VERA) Skyrocketed On MondayJune 3 at 3:15 AM | msn.comVera Therapeutics Shares Climb on Positive Trial Results for Kidney Disease DrugJune 2 at 5:13 PM | marketwatch.comAtacicept Significantly Reduces Proteinuria in IgA Nephropathy TrialJune 2 at 5:13 PM | empr.comVera drug scores in closely watched study in rare kidney diseaseJune 2 at 5:13 PM | biopharmadive.comVera Therapeutics Shares Jump 80% on Strong Phase 3 Trial Results for AtaciceptJune 2 at 5:13 PM | msn.comVera rises after success in late-stage trial for IgA nephropathy treatmentJune 2 at 5:13 PM | msn.comVera Therapeutics reports positive results from trial of kidney disease drugJune 2 at 5:13 PM | statnews.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst UpgradeJune 2 at 10:35 AM | marketbeat.comVera shares skyrocket as kidney disease drug succeeds in late-stage trialJune 2 at 9:06 AM | reuters.comKidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial DataJune 2 at 9:01 AM | benzinga.comVera Therapeutics (NASDAQ:VERA) Price Target Raised to $85.00 at HC WainwrightJune 2 at 8:57 AM | marketbeat.comVera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary EndpointJune 2 at 7:19 AM | quiverquant.comVera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA NephropathyJune 2 at 6:30 AM | globenewswire.comMillennium Management LLC Trims Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)June 1 at 3:44 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Up 5.7% - Time to Buy?May 30, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.33 Consensus PT from AnalystsMay 29, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by AnalystsMay 27, 2025 | marketbeat.comCantor Fitzgerald maintains Vera Therapeutics at OverweightMay 26, 2025 | uk.investing.comBNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA)May 23, 2025 | marketbeat.comWoodline Partners LP Acquires 201,573 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative GainsBroadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostBy Leo Miller | May 7, 2025View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?AUTL, VERA, DYN, and GPCR Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.91 +0.16 (+9.14%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.52%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Dyne Therapeutics NASDAQ:DYN$12.70 +0.74 (+6.19%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$12.72 +0.02 (+0.16%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Structure Therapeutics NASDAQ:GPCR$21.79 +0.03 (+0.14%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$22.07 +0.28 (+1.28%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Vera Therapeutics NASDAQ:VERA$31.74 +12.79 (+67.49%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$31.52 -0.22 (-0.68%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
